References

1. Brandt JT. Overview of hemostasis. In McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Baltimore, Md: Lippincott Williams and Wilkins; 2002:987-1009.
2. Liu MC, Kessler CM. A systemic approach to the bleeding patient. In Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: W.B. Saunders; 2002:181-196.
3. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med. 2002 Feb; 126(2):133-146.
4. Triplett DA. Coagulation abnormalities. In McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Baltimore, Md: Lippincott Williams and Wilkins; 2002:1033-1049.
5. Van Cott EM, Laposata M. Coagulation. In Jacobs DS, Oxley DK, eds. Laboratory test Handbook. Hudson, Ohio: Lexi-Comp; 2001:327-358.
6. Adcock DM, Jensen R, Johns CS, Macy PA. Coagulation Handbook. Austin, Texas: Esoterix Coagluation; 2002.
7. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997; 107(1):105-110.
8. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998; 109(6):754-757.
9. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995; 74(4):1185-1190.
10. Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost. 2001 Oct; 7(4):241-258.
11. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy. Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001; 103(24):2994-3018.
12. Adcock DM. Laboratory evaluation of venous thrombosis risk. Clin Hemost Rev. Dec 2003; 17(12):1,2,5,6,8.
13. Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: Diagnosis and treatment. Hematol (Am Soc Hematol Educ Program). 2003:520-539.
14. Marques MB. Testing for genetic predisposition to venous thrombosis. MLO. 2002; 1:8-13.
15. Marlar RA, Adcock DM. The multi-factorial threshold model of thrombotic risk. Clin Hemost Rev. June 2003; 17(6):1,2,4-6.
16. Triplett DA. Thrombophilia. In McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Baltimore, Md: Lippincott Williams and Wilkins; 2002:1033-1049.
17. Jenson R. The antiphospholipid antibody syndrome. Clin Hemost Rev. November, 2001; 15(11):1-4.
18. Alving BM. The antiphospholipid syndrome: clinical presentation, diagnosis and patient management. In Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: W.B. Saunders; 2002:181-196.
19. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002 Mar 7; 346(10):752-763.
20. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun. 2000; 15(2):163-172.
21. Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol. 1999; 6(6):775-782.
22. Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests. Lupus. 1998; 7 Suppl 2:S144-S148.
23. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003 Jul; 1(7):1504-1514.
24. Schjetlein R, Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am J Clin Pathol. 1995 Jan; 103(1):108-111.